NEW YORK, April 18 - In a sign that RNAi is truly creating a buzz in the life sciences community, Ribozyme Pharmaceuticals announced Wednesday that it was changing its name to Sirna Therapeutics, and changing its stock symbol to RNAI.

 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Labs in the US and South Korea are hoping to bring the woolly mammoth back from beyond extinction, Newsweek writes.

Geneticist Adam Rutherford speaks with National Geographic about paleogenetics, race, and more.

Researchers link genetic links between education and smoking and longevity.

In PNAS this week: influence of gene environment interactions on polygenic traits, epigenetic features affecting fruit fly foraging, and more.